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Binding of platelet factor four (PF 4) to glomerular polyanion. Synthet-
ic polycations have been shown to bind to glomerular polyanion (GPA)
and increase glomerular permeability. Here, we show that human
platelet factor 4 (PF 4), a platelet secretory protein, binds to GPA. The
following methods were used to assess PF 4 binding to GPA: (1)
Sections of human and rat renal cortex were incubated with PF 4 or PF
4 was injected intravenously into rats followed by immunofluorescence
techniques; (2) '251-PF 4 was added to isolated glomerular basement
membrane (GBM) suspensions and binding assessed isotopically; (3) PF
4 was perfused through rat kidneys ex vivo followed by immunoper-
oxidase methods for electron microscopy (EM). In vitro and in vivo, PF
4 bound to the mesangium and linearly to capillary walls. Isotopic
studies showed dose-dependent saturable binding of PF 4 to GBM
which was reversed by heparin. By EM, PF 4 binding sites were
resolved in the GBM, particularly in the laminae rarae as punctate
densities similar in distribution to anionic sites revealed by cationic
dyes. Also, endothelial and epithelial cell surfaces stained. An ionic
interaction between PF 4 and GPA was indicated by elimination of
staining by washing PF 4-treated sections with buffer containing 1.0 and
3.0 M NaC1 or with heparin. Pretreatment of rats with polyethylenei-
mine (a synthetic polycation) blocked PF 4 binding. Heparin adminis-
tration in vivo removed previously bound PF 4. By virtue of its affinity
for GPA and behavior like a polycation, PF 4 may alter glomerular
permeability and play a role in glomerular disease.
Liaison du facteur plaquettaire quatre (PF 4) aux polyanions gloméru-
laires. 11 a été démontré que des polycations synthétiques se lient aux
polyanions glomérulaires (GPA) et augmentent Ia perméabilité gloméru-
laire. Ici, nous montrons que le facteur plaquettaire 4 (PF 4), une
protéine sécrétoire plaquettaire, se lie au GPA. Les méthodes suivantes
ont été utilisées pour préciser Ia liaison du PF 4 au GPA: (1) Des
sections de cortex de reins d'homme et de rat ont étd incubées avec du
PF 4, ou le PF 4 a été injecté par voie intraveineuse a des rats, avec
ensuite techniques d'immunofluorescence; (2) '251-PF 4 a été ajouté a
des suspensions de membranes basales glomerulaires isolées (GBM) et
Ia liaison mesurée de facon isotopique; (3) le PF 4 a été perfuse a des
reins de rat ex-vivo avec ensuite technique d'immunoperoxidase pour
microscopie électronique (EM). In vitro et in vivo, Ic PF 4 se liait au
mCsangium, et de facon Iinéaire aux parois capillaires. Des etudes
isotopiques ont montré une liaison saturable, dose dependante, du PF 4
aux GBM, qui était reversible par de l'héparine. En EM, les sites de
liaison du PF 4 étaient visibles sur Ia GBM, surtout sur les laminae
rarae, sous forme de densifications ponctuCes, identiques aux sites de
distribution anionique révélés par les colorants cationiques. Egalement,
les surfaces cellulaires endothCliales et épithéliales étaient colorées.
line interaction ionique entre PF 4 et GPA était indiquCe par l'élimina-
tion de Ia coloration en lavant des sections traitées au PF 4 avec un
tampon contenant 1,0 ou 3,0 M NaCI, ou avec de l'héparine. Le
prétraitement de rats avec du polyethylènimine (un polycation synthéti-
que) a bloque Ia liaison du PF 4. L'administration d'heparine in-vivo a
enlevé Ic PF 4 préalablement liC. En raison de son affinité pour le PGA,
et de son comportement comme un polycation, PF 4 pourrait altérer Ia
permCabilité glomérulaire et jouer un role dans les glomerulopathies.
The glomerular basement membrane (GBM) contains a num-
ber of polyanionic substances which impart an overall electro-
negative charge to the structure, forming a charge barrier to
circulating anionic molecules. Recent studies indicate that
circulating exogenous synthetic polycations can bind to polyan-
ion within the GBM [1—4]. Such binding to glomerular polyan-
ion has been shown to neutralize the electrostatic barrier
leading to alterations in glomerular permeability to circulating
anionic macromolecules [1, 4—6]. Preliminary studies from this
laboratory have also shown that a synthetic polycation, poly-
ethyleneimine (PE!) can increase glomerular permeability and
lead to enhanced deposition of immune complexes [7]. This
concept is of considerable clinical importance since a number of
inflammatory cells and platelets contain a variety of secretory
cationic proteins, which upon release during disease processes,
might potentiate immune complex deposition and glomerular
injury at a local level. Indeed, platelets have been implicated as
mediators in glomerulonephritis [8—11].
If endogenous cationic proteins were to influence glomerular
permeability, obviously they must first interact with glomerular
polyanion (GPA). The objective of the present study was to
examine the potential of a platelet-derived secretory protein,
platelet factor 4 (PF 4), which behaves like a polycation, to bind
to GPA in the glomerular capillary wall, particularly to the
GBM.
Methods
Platelet factor 4 (PF 4). Human PF 4 was purified as
previously described [12]. Briefly, outdated platelet concen-
trates, generously supplied by Wadley Institutes of Molecular
Medicine, Dallas, Texas, were washed in citrate saline buffer,
then lysed by repeated freeze-thawing. Following centrifuga-
tion of membranes, the PF 4-enriched supernate was passed
through a heparin-e-aminocaproic acid-Sepharose column, and
washed extensively with buffer. Purified PF 4 was eluted from
the column utilizing a gradient of 0.5 to 3.0 M NaCI in 0.005 M
sodium barbital buffer, pH 7.4. Purity and activity of PF 4
fractions were assayed according to the methods outlined
previously [12]. Antiserum against purified PF 4 was generated
and harvested from New Zealand white rabbits by standard
laboratory techniques and was shown to form one line of
identity with the purified antigen in immunodiffusion plates.
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PF 4 binding to kidney cortical tissue. Binding of PF 4 to
human and rat kidney cortex was assessed by indirect immuno-
fluorescence according to the following procedure: PF 4 (590 to
720 tg/m1) in 0.6 M NaCl, 0,005 M barbital buffer, pH 7.4 was
diluted 1:4 with 1.0% bovine serum albumin in water. Human
kidney cortex was acquired as surplus biopsy or autopsy tissue
from the Department of Pathology, The University of Texas
Health Science Center at San Antonio or from the South Texas
Organ Bank Inc., San Antonio, Texas. Only tissue samples
determined to be disease-free by pathological examination were
used in these experiments. Rat kidneys were washed free of
blood by perfusion with 0.02 M phopshate buffered saline, pH
7.4 (PBS). The kidney cortical tissue was trimmed and then
frozen with Cryokwik°° liquid freon or in isopentane pre-chilled
in liquid nitrogen. Frozen sections 6 to 8 sm thick were cut
using a cryostat (Model CTI, International Equipment Compa-
ny, Needham Heights, Massachusetts). PF 4 was then layered
onto the tissue section and allowed to incubate for 15 mm,
washed with barbital buffered saline containing 0.15 M NaCI in
0.005 M barbital, pH 7.4 (BBS), then followed by incubation
with rabbit anti-human PF 4 serum. Following three additional
washes with BBS, the sections were incubated with fluorescein-
conjugated IgG fraction of goat anti-rabbit IgG (Cappel Labora-
tories, Westchester, Pennsylvania) followed again by three
washes of BBS and then mounted. Controls consisted of
layering diluent without PF 4 in place of the PF 4 solution
and/or normal non-immune rabbit serum in place of the primary
anti-PF 4 serum. Sections were examined using a Zeiss Univer-
sal II Research microscope equipped for epifluorescence using
a standard FITC filter set supplemented with a KPS6O short-
wave pass filter for optimal illumination for fluorescein.
To examine an ionic interaction between PF 4 and GPA,
sections were washed after incubation with PF 4 with barbital
buffers containing progressively increasing concentrations of
sodium chloride (0.15, 0.5, 1.0, or 3.0 M). In a separate series of
experiments, sections of kidney cortex were incubated with PF
4, washed with BBS, followed by incubation with sodium
heparin (isolated from porcine mucosa, Biosynth, Inc., Chica-
go, Illinois) at concentrations ranging from 80 sg/ml to 10
mg/mi). The sections were washed with BBS and indirect
immunofluorescence procedures were performed as outlined
above.
Binding of '251-PF 4 to isolated glomerular basement
membrane (GBM) in vivo
Preparation of GBM. Glomeruli were isolated from kidneys
of 30 male Sprague-Dawley rats (Harlan SD, Madison, Wiscon-
sin) by sequential sieving through graded sized mesh screens
[13] and purified by osmotic lysis in distilled water, treatment
with deoxyribonuclease I (Sigma Chemical Company, St. Lou-
is, Missouri) and sodium deoxycholate according to the method
of Meezan, Hjelle, and Brendel [14]. Following extensive
washing with PBS, the isolated GBMs were fragmented by brief
sonication (3 x 30 sec bursts) on ice using an ultrasonic cell
disruptor®, (Model W-220F, Heat Systems Ultrasonics, Inc.,
Plainview, New York) at an amplitude setting of 6. Protein
concentration of GBM suspensions was measured using the
method of Lowry et al [15].
Preparation of '251-PF 4. lodination of PF 4 was performed
by reacting 10 g of PF 4 with 50 g chioramine T plus 1 mCI
tude setting of 6. Protein concentration of GBM suspensions
was measured using the method of Lowry et al [15].
Preparation of '251-PF 4. lodination of PF 4 was performed
by reacting 10 sg of PF 4 with 50 sg chloramine T plus one mCI
of sodium '25lodide (Amersham, Arlington Heights, Illinois)
[16]. The PF 4 sample was then passed through a heparin
sepharose column and free 1251 was eliminated by several
washes with BBS. Bound '251-PF 4 was eluted from the column
by washing it with 3.0 M NaCI barbital buffer and collecting it in
0.5 ml fractions. Radioactivity of each fraction was assessed
using a gamma scintillation counter (Beckman Instruments,
Fullerton, California). The two fractions with the highest num-
ber of counts were pooled and used fresh or stored at —25°C for
subsequent studies. This method produced '251-PF 4 with an
activity of approximately 10,000 cpm/ng (6.0 x 106 cpm/mI).
'251pF 4 (0.1 ml) was added to unlabeled PF 4 in 0.6 M NaCI to
give a final concentration of 500 g/ml of the platelet protein.
Polyethylene glycol (6000 daltons) was added to the solution to
make a final concentration of 0.88% to reduce nonspecific
adherence of PF 4 to the sides of pipets and test tubes during
subsequent dilutions [17]. This stock solution was then diluted
to make graded concentrations of PF 4 ranging from 50 to 500
jig/mi.
Protocol. To examine PF 4 binding to isolated GBM in vitro
the following experiments were performed:
(1) GBM (15 jig in 100 uI) was added to 800 d of 0.02 M PBS
containing 1% bovine serum albumin followed by the addition
of 100 jii of PF 4 dilutions ranging in concentration from 0.5 jig
to 100 jig.
(2) To examine an ionic interaction between PF 4 and the
GBM, sodium heparin (200 jig) was added to the GBM suspen-
sion 10 mm following the addition of PF 4. Background counts
were assessed by adding the PF 4 dilutions into separate tubes
containing buffer without GBM. The tubes were allowed to
incubate for 2 hr at room temperature on a tilting mixer, then
washed three times by repeated centrifugation at x 3 ,000g and
resuspension in buffer. Total counts were determined in sepa-
rate tubes containing 100 utl of each P1' 4 dilution. Relative
amounts of PF 4 in each tube were determined by measuring
and recording counts per minute and comparing these with total
counts in tubes of known PF 4 concentrations. PF 4 bound to
GBM was determined by subtracting background counts from
counts obtained from tubes in which PF 4 was added to GBM
suspensions.
Binding of PF 4 to glomerular structures in vivo. The
following studies were performed to assess the potential of
purified human PF 4 to bind to kidney polyanion in vivo
following intravenous administration into male Sprague-Dawley
rats. Rats were lightly anesthetized with ether. Then 0.5 ml of
0.6 M NaCl barbital buffer containing 125 or 250 jig of purified
PF 4 was injected into a tail vein. Control rats received an equal
volume of 0.6 M NaC1, 0.15 M sodium barbital, pH 7.4, without
PF 4. Five minutes following injection of PF 4 or diluent the
animals were sacrificed, kidneys were removed, and cortical
tissue samples were trimmed and frozen for subsequent indirect
immunofluorescence as outlined above.
To further assess an ionic interaction of PF 4 with GPA, rats
were lightly anesthetized with ether, then given polyethylenei-
mine (PEI), 1800 daltons (Arsynco Inc., Carlstadt, New Jersey)
prior to administration of PF 4. Since PEI is known to bind to
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GPA [2, 3] prior treatment with this synthetic polycation was
anticipated to block PF 4 binding. PEI was diluted in 0.05 M
PBS, pH 7.2, to make a final solution containing 0.5% PEI with
a pH of 7.4. In control experiments 0.05 M PBS without PEI
was used. Four rats were given PEI at a dose of 15 jxglg body wt
i.v. followed 5 mm later by 125 g of PF 4. An equal number of
control rats were given PBS followed by the same dose of PF 4.
Five minutes following PF 4 the rats were sacrificed, kidneys
were removed, and cortical tissue samples were trimmed and
frozen in isopentane pre-cooled in liquid nitrogen. Cortical
tissue samples were sectioned and indirect immunofluores-
cence was performed as outlined above. Similarly, post-treat-
ment with heparin, which has a high affinity for PF 4 [18] may
remove PF 4 from GPA. To examine this hypothesis, four rats
were given an intravenous injection of 125 ig of PF 4, i.v.,
followed 5 mm later by 500 tg of sodium heparin in 0.5 ml of
PBS. Control rats received an equal dose of PF 4 followed by
PBS without heparin. Five minutes after the heparin injection
or PBS the rats were sacrificed, kidneys were removed, sliced,
and frozen. Localization of PF 4 was assessed by immunofluo-
rescence microscopy.
U!! ra structural localization of PF 4 binding sites. PF 4
binding sites in the glomerular capillary wall following intrare-
nal perfusion were assessed at the ultrastructural level utilizing
immunoperoxidase methodology. A total of six rats were anes-
thetized with sodium pentobarbital, 60 mg/kg i.p. The left
femoral artery was gently dissected free from connective tissue
and a PE-lO catheter was threaded along the artery up into the
abdominal aorta until the tip was localized just below the left
renal artery. The catheter was then tied in place with suture.
The left renal vein and the aorta above the left renal artery were
freed from surrounding connective tissue and all arterial tribu-
taries from the aorta between the catheter and the left renal
artery were ligated. Immediately prior to perfusion, the aorta
above the left renal artery was clamped and perfusion of
oxygenated Krebs-Henseleit saline (KHS) buffer started imme-
diately followed by puncture of the left renal vein. The kidney
was washed free of blood by perfusion of 5 ml warm (37°C)
KHS over 1 mm followed by perfusion of 500 to 600 sg of PF 4
in 3 ml of saline containing 1% BSA (N = 3) or diluent alone
[0.15 M NaCI, 1% BSA without PF 4 (N = 3)]. After pefusion of
PF 4 or diluent alone the kidneys were washed with 4 ml of
KHS over 3 mm followed by perfusion of 2 ml of fixative
solution comprised of 3.0% glutaraldehyde, 1.4% paraformalde-
hyde in cacodylate buffer, pH 7.4. Aldehyde groups were
quenched by perfusion of 10 ml 0.1 M Tris-HCI, pH 7.4,
immediately after fixation. Kidney cortex was sliced and placed
back into Tris-HCI for 4 to 5 days, then several slices were
frozen in pre-cooled isopentane and stored at —25°C for later
use. Forty to sixty micrometers thick sections were cut from
the remaining tissue using a tissue chopper (Smith-Farquhar-
Sorvall Newton, Connecticut) and incubated in immunorea-
gents according to the following time schedule: (1) 2 hr in
normal goat IgG; (2) 3 hr in anti-PF 4 serum, normal rabbit
serum or anti-PF 4 serum adsorbed with PF 4, and (3) 2 hr in
horseradish peroxidase conjugated F(ab')2 fragment of goat
anti-rabbit IgG (Cappel Laboratories, Westchester, Pennsylva-
nia). Tissue sections were washed three times with PBS (10 mm
each), between and following all incubation steps. Peroxidase
activity was revealed according to the method of Graham and
Fig. 1. Immunofluorescence localization of PF 4 in a section of human
renal cortex following incubation with the platelet protein and subse-
quent washing with barbital buffered saline (BBS). Localization of PF 4
occurs in glomerular peripheral capillary loops and the mesangium.
Also peritubular capillaries and/or tubular basement membrane stain for
PF 4. (x250)
Fig. 2. Same as Figure 1, except a wash with buffer containing 1.0 M
NaCI in place of BBS. After incubation with PF 4, washing with high
molar salt (1.0 and 3.0 M) removed PF 4 from the section as illustrated
by minimal background staining. (x250)
Fig. 3. Same as Figure 1 except after incubating with PF 4, a sub-
sequent incubation with heparin (10 g/ml). PF 4 has been removed
from the section as indicated by minimal background staining. (x250)
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Karnovsky [19]. The peroxidase reaction was not allowed to
proceed beyond 2 mm. Sections were washed, osmicated for 30
mm with 2.0% osmium tetroxide (0s04) then dehydrated and
flat-embedded in Epon using standard laboratory techniques.
Sliver-gold sections of glomeruli were cut from cross sections of
the tissue block, examined, and photographed using an electron
microscope (Philips 301). In addition, the indirect immunoper-
oxidase technique was performed on 6-jim frozen tissue sec-
tions for light microscopy in a similar manner as described
above except that sections were incubated for 30 mm in each
immunoreagent and the peroxidase reaction time was allowed
to progress for 5 to 15 mm.
Results
Localization of PF 4 in human and rat kidney sections
incubated with the platelet protein showed similar positive
immunofluorescent staining patterns. All sections showed a
strong binding of PF 4 to the walls of peripheral capillary loops
and to the mesangium (Fig. 1). In addition, peritubular capillar-
ies and/or tubular basement membranes showed strong staining
for PF 4 which tended to be more intense in human tissue
sections when compared to sections of rat kidney. Since PF 4
was layered onto cut tissue sections, exposed cellular anionic
substances were available for PF 4 binding, evidenced by a
higher than usual background fluorescence. Sections receiving
diluent without PF 4 showed only a minimal background
including a slight nuclear staining. Washing the sections with
0.5 M NaCI in barbital buffer following PF 4 enhanced staining
of glomerular structures and reduced background staining.
Staining was readily removed by washing the sections in
barbital buffer containing 1.0 or 3.0 M NaCI (Fig. 2). Treatment
of sections with heparin (80 jig/ml to 10 mg/mI) also removed PF
4 as indicated by only faint staining of glomerular and peritubu-
lar structures (Fig. 3).
PF 4 binding to isolated GBM. The total amount of PF 4
nonspecifically bound to surfaces of plastic tubes was less than
4% of the total amount of PF 4 bound to GBM. Radiolabelled
PF 4 (10 to 100 jig) showed a strong affinity for isolated GBM. A
linear relationship between the amount of t2sIPF 4 added to the
GBM suspension and the amount bound was shown to occur
between 10 and 40 jig of added 1251-PF 4 (Fig. 4). However, this
relationship diminished when more than 40 jig of '251-PF 4 were
added to the GBM suspension indicating saturation of PF 4
binding sites. The addition of 200 jig of heparin to the suspen-
sion 10 mm following PF 4 almost completely abolished PF 4
binding, showing a maximum binding of 4.6% of that observed
with GBM plus PF 4, in the absence of heparin (Fig. 4).
Administration ofPF4 in vivo. PF 4 showed a high affinity for
GBM and the mesangium as indicated by strong staining of
these structures by immunofluorescence following administra-
tion of as little as 125 jig of purified PF 4 (Fig. 5). The staining
intensity tended to depend on the dose of PF 4 injected and a
dose of 250 jig produced more intense immunofluorescent
staining of glomerular structures. In addition, peritubular capil-
laries and tubular basement membranes stained; but staining
intensity was much less than that found within glomerular
structures (Fig. 5). Control rats and tissue sections receiving
diluent without PF 4 or normal non-immune serum in place of
primary anti-PF 4 serum showed negligible background stain-
ing. Prior administration of PEI blocked PF 4 binding (Fig. 6).
GBM + PF-4
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Fig. 4. Binding of '251-PF 4 to isolated glomerular basement membrane(GBM). A linear relationship between the amount of PF 4 added and the
amount bound to GBM exists between 10 to 40 zg. This relationship
diminishes from 40 to 100 gig. Heparin eliminates most of PF 4 binding
to GBM.
Fig. 5. Glomerular immunofluorescence localization of human PF 4
after intravenous injection into a rat. Strong staining of peripheral
capillary loops and the mesangium is apparent. (x330)
Fig. 6. Rat glomerulus stained for PF 4 5 mm after an injection of
polyethyleneimine (PEJ) followed by PF 4. Pre-treatment with PEL
blocked PF 4 binding as indicated by the absence of glomerular staining
when compared to Figure 5. (x330)
Similarly, heparin administration following injection of PF 4
eliminated staining, indicating removal of the platelet protein
from binding sites (not shown).
Light microscopical localization of PF 4 following perfusion
revealed intense staining of the GBM in a linear pattern similar
to that observed by immunofluorescence following intravenous
injection (Fig. 7). In addition, the reaction product was also
observed on proximal tubular brush border and within apical
vesicles. When non-immune or adsorbed serum was used in
place of primary anti-PF 4 serum, control rats and tissue
sections were negative (Fig. 8). Similarly, tissue samples from
kidneys perfused with diluent alone were negative.
Ultrastructural localization of PF 4 by immunoperoxidase
staining revealed that the platelet protein was bound to multiple
sites throughout the glomerular capillary wall, particularly
within the GBM (Fig. 9). Reaction product was observed
throughout the GBM but tended to localize in small punctate
sites in both lamina rarae, especially in the lamina rara externa
(Fig. 9). Reaction product was also observed on the surfaces of
endothelial and epithelial cells, but the strongest staining was
observed just beneath epithelial cells adjacent to the GBM.
Staining was completely absent in non-immune serum control
rats (Fig. 10); however, a very faint staining of glomerular
structures was observed in kidneys perfused with diluent with-
out PF 4, possibly reflecting cross reaction with endogenous rat
PF 4 released during surgical procedures.
Discussion
The present study allows the following conclusions with
regard to the interaction of PF 4 with GPA: (I) Purified PF 4
binds avidly to human and rat GBM and epithelial and endothe-
hal cell surfaces; (2) PF 4's interaction with glomerular struc-
tures is ionic in that binding can be blocked by prior exposure of
GPA with a synthetic polycation PEI and can be removed by
post-treatment with heparin or high ionic strength buffer; (3) PF
4 binding sites in rat GBM, revealed by immunoperoxidase
cytochemistry, are heterogeneous in distribution and show a
similar pattern as described for glomerular anionic sites stained
by cationic dyes.
PF 4 is a platelet-specific protein (31,000 daltons) [201 corn-
plexed to a proteoglycan carrier rich in chondroitin sulfate [211
contained in alpha granules. The PF 4-carrier complex readily
undergoes dissociation in high ionic strength buffers or through
interaction with the glycosaminoglycan heparin [211. Although
PF 4 is not classically considered a "cationic macromolecule"
(p1 = 7.6), due to its unique distribution of lysine residues, it
behaves like a polycation and strongly interacts with negatively
charged sulfate groups on glycosaminoglycans [181.
Recent studies have shown that PF 4 can also interact with
heparan sulfate on endothelial cell surfaces in culture [221,
demonstrating the binding of this platelet protein in a living
biological system. Since the GBM is comprised in part of
heparan sulfate [23—251 and mesangial and epithelial cells are
known to synthesize glycosaminoglycans in culture [26, 271, PF
4 binding to glomerular structures may, at least in part, be
attributed to its interaction with glycosaminoglycans. Heparin
strongly binds to PF 4 in vitro [181 and has recently been shown
to displace PF 4 from heparan sulfate present on endothelial
surfaces [22]. Our studies also showed that heparin could
remove PF 4 from glornerular binding sites, in vitro and in vivo,
Fig. 8. Control for tissue section depicted in Figure 7. The section was
treated with non-immune rabbit serum in place of anti-PF 4 serum
followed by subsequent peroxidase staining procedures. (x400)
supporting such a PF 4-heparan sulfate interaction. Even
though PF 4 is known to have a strong affinity for N-sulfated
glycosaminoglycans, this interaction is ionic and binding to
other glomerular polyanionic constituents such as the sulfated
glycoprotein entactin [28] and sialic acid containing glycopro-
teins such as laminin [29—32] and fibronectin [30, 33—35]; others
as yet undefined, cannot be excluded. The ultrastructural
immunoperoxidase observations in our study support multiple
PF 4 binding sites in that distribution of reaction product was
heterogenous (punctate densities in the laminae rarae in addi-
tion to diffuse GBM staining and endothelial and epithehial cell
coat staining). Our studies do not define which polyanionic
component within the GBM comprises the major binding site
for PF 4. An answer to this question may await defined studies
utilizing enzymatic attack on specific polyanionic moieties
followed by isotopic PF 4 binding assays.
The GBM, by virtue of its high polyanionic content, forms a
charge barrier to circulating anionic macromolecules [36—40]. A
number of recent studies have shown that administration of
PF 4 binding to glomerular polyanion 763
FIg. 7. Immunoperoxidase localization of human PF 4following intrare-
awl perfusion of the platelet protein. Note the linear staining ol
glomerular peripheral capillary loops. (x400)
S
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Fig. 9. lmniunoperox,dase rytoe/ie,ntral !ocahzat,on of PF 4 following
intrarenal perfusion. Reaction product is present throughout the GBM
but particularly at small punctate sites in the laminae rarae (arrows).
Also, surfaces of endothelial and epithelia! cells stain for PF 4.
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Fig. 10. Contra/for Figure 9. The tissue sample was treated with non-
immune rabbit serum in place of primary anti-PF 4 serum. Note the
absence of reaction product throughout the glomerular capillary wall,
Only osmium staining is apparent resulting in low contrast and detail.
(x 69,000)
synthetic polycations in vivo can neutralize GPA and lead to
alterations in permeability to circulating macromolecules [1, 4—
6]. It is also of considerable interest that removal of heparan
sulfate by enzyme digestion with heparitinase increases glomer-
ular permeability to the tracer macromolecule ferritin [40].
Neutralization of GPA and the resultant perturbation of glomer-
ular permeability is of particular importance since endogenous
polycations may be released from inflammatory cells and/or
platelets during glomerular disease processes; these may bind
to GPA and induce permeability defects within the GBM.
Previous studies in our laboratory have shown that a synthet-
ic polycation, PEI can increase glomerular permeability to
passively administered antigen and antibody and lead to en-
hanced deposition and altered distribution of immune complex-
es [7]. Endogenous cationic proteins once released may behave
in a similar fashion at a local level and affect the GBM. This
concept has been supported by Camussi et al [41] in a recent
study describing GBM localization of neutrophilic cationic
proteins associated with loss of GPA in lupus nephritis. Plate-
lets have been implicated as mediators in glomerulonephritis
[8—ill supporting such a role for PF 4 and other platelet
polycationic proteins as mediators in immune complex deposi-
tion. Also, blood levels of PF 4 are known to be markedly
elevated during glomerulonephritis [11].
PF 4 is released from platelets as a high molecular weight
proteoglycan-PF 4 complex. The degree of dissociation of PF 4
from its carrier following release is unknown. PF 4 has a much
higher affinity for heparan sulfate than chondroitin sulfate [18,
21]. Thus, it is likely that transfer of PF 4 from its chondroitin
sulfate-rich carrier to heparan sulfate or other GPA within the
glomerular capillary wall may occur during glomerular disease.
Intraglomerular activation of platelets would be expected to
result in high concentrations of PF 4 in the milieu directly
adjacent to and accessible to the GBM. Our studies do not
address the above issues, but they do indicate that dissociated,
purified PF 4 is capable of avid binding to GPA. That free PF 4
binds to GPA in sufficient quantities to perturb glomerular
permeability during glomerular disease processes remains to be
determined. It is important to point out that a myriad of other
cationic proteins may also be released from platelets and
leukocytes during glomerulonephritis and collectively may in-
fluence giomerular permeability. Such platelet-GBM interac-
tions and permeability perturbations would occur at a local
level and experimental reproduction of this phenomenon may
require intravenous administration of large quantities of platelet
proteins. Studies are currently underway in our laboratory to
examine the potential of PF 4 to induce glomerular permeability
defects and its role in glomerular disease processes.
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